These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 17853429)
1. Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. Komura H; Iwaki M J Pharm Sci; 2008 May; 97(5):1775-800. PubMed ID: 17853429 [TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences. Komura H; Iwaki M Drug Metab Rev; 2011 Nov; 43(4):476-98. PubMed ID: 21859377 [TBL] [Abstract][Full Text] [Related]
3. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Lampen A; Christians U; Guengerich FP; Watkins PB; Kolars JC; Bader A; Gonschior AK; Dralle H; Hackbarth I; Sewing KF Drug Metab Dispos; 1995 Dec; 23(12):1315-24. PubMed ID: 8689938 [TBL] [Abstract][Full Text] [Related]
4. Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys. Nishimuta H; Sato K; Mizuki Y; Yabuki M; Komuro S Drug Metab Dispos; 2010 Nov; 38(11):1967-75. PubMed ID: 20702772 [TBL] [Abstract][Full Text] [Related]
5. Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine. Martignoni M; Groothuis G; de Kanter R Drug Metab Dispos; 2006 Jun; 34(6):1047-54. PubMed ID: 16565172 [TBL] [Abstract][Full Text] [Related]
6. Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys. Ogasawara A; Kume T; Kazama E Drug Metab Dispos; 2007 Mar; 35(3):410-8. PubMed ID: 17142564 [TBL] [Abstract][Full Text] [Related]
7. Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells. Ikemura K; Urano K; Matsuda H; Mizutani H; Iwamoto T; Okuda M J Pharmacol Exp Ther; 2009 Jan; 328(1):249-55. PubMed ID: 18842703 [TBL] [Abstract][Full Text] [Related]
8. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. Lampen A; Zhang Y; Hackbarth I; Benet LZ; Sewing KF; Christians U J Pharmacol Exp Ther; 1998 Jun; 285(3):1104-12. PubMed ID: 9618413 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam. Kuze J; Mutoh T; Takenaka T; Oda N; Hanioka N; Narimatsu S Xenobiotica; 2013 Jul; 43(7):598-606. PubMed ID: 23282066 [TBL] [Abstract][Full Text] [Related]
10. A Comprehensive Investigation of Dog Cytochrome P450 3A (CYP3A) Reveals a Functional Role of Newly Identified CYP3A98 in Small Intestine. Uno Y; Jikuya S; Noda Y; Murayama N; Yamazaki H Drug Metab Dispos; 2023 Jan; 51(1):38-45. PubMed ID: 35772769 [TBL] [Abstract][Full Text] [Related]
11. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Prueksaritanont T; Gorham LM; Hochman JH; Tran LO; Vyas KP Drug Metab Dispos; 1996 Jun; 24(6):634-42. PubMed ID: 8781778 [TBL] [Abstract][Full Text] [Related]
12. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. Paine MF; Khalighi M; Fisher JM; Shen DD; Kunze KL; Marsh CL; Perkins JD; Thummel KE J Pharmacol Exp Ther; 1997 Dec; 283(3):1552-62. PubMed ID: 9400033 [TBL] [Abstract][Full Text] [Related]
13. Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. Nishimura T; Amano N; Kubo Y; Ono M; Kato Y; Fujita H; Kimura Y; Tsuji A Drug Metab Dispos; 2007 Aug; 35(8):1275-84. PubMed ID: 17470527 [TBL] [Abstract][Full Text] [Related]
14. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Gertz M; Harrison A; Houston JB; Galetin A Drug Metab Dispos; 2010 Jul; 38(7):1147-58. PubMed ID: 20368326 [TBL] [Abstract][Full Text] [Related]
15. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. Fenneteau F; Poulin P; Nekka F J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982 [TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: in vitro and in vivo studies in rats. Hirunpanich V; Murakoso K; Sato H Int J Pharm; 2008 Mar; 351(1-2):133-43. PubMed ID: 18082981 [TBL] [Abstract][Full Text] [Related]
17. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Kharasch ED; Hoffer C; Whittington D; Sheffels P Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986 [TBL] [Abstract][Full Text] [Related]
18. Alprazolam as an in vivo probe for studying induction of CYP3A in cynomolgus monkeys. Ohtsuka T; Yoshikawa T; Kozakai K; Tsuneto Y; Uno Y; Utoh M; Yamazaki H; Kume T Drug Metab Dispos; 2010 Oct; 38(10):1806-13. PubMed ID: 20584745 [TBL] [Abstract][Full Text] [Related]
19. Intestinal first-pass metabolism of CYP3A4 substrates. Kato M Drug Metab Pharmacokinet; 2008; 23(2):87-94. PubMed ID: 18445987 [TBL] [Abstract][Full Text] [Related]
20. Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans. Nishimuta H; Sato K; Mizuki Y; Yabuki M; Komuro S Drug Metab Pharmacokinet; 2011 Jun; 26(3):300-6. PubMed ID: 21383522 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]